Hims & Hers Health's fair value estimate rose 10% to $26.82, driven by optimism over its Novo Nordisk partnership and new product options like labs, hormone programs, and global expansion. However, concerns about margins, regulation, and execution keep analyst opinions divided. The company is targeting the GLP-1 market in Canada after a Novo Nordisk patent expiry.